BeOne Medicines AG (SHA:688235)
China
· Delayed Price · Currency is CNY 279.25
-0.98 (-0.35%)
Dec 5, 2025, 3:00 PM CST
BeOne Medicines AG Revenue
BeOne Medicines AG had revenue of 10.05B CNY in the quarter ending September 30, 2025, with 43.11% growth. This brings the company's revenue in the last twelve months to 35.40B, up 52.67% year-over-year. In the year 2024, BeOne Medicines AG had annual revenue of 27.81B with 59.51% growth.
Revenue (ttm)
35.40B
Revenue Growth
+52.67%
P/S Ratio
7.14
Revenue / Employee
3.22M
Employees
11,000
Market Cap
252.62B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 27.81B | 10.38B | 59.51% |
| Dec 31, 2023 | 17.43B | 7.67B | 78.53% |
| Dec 31, 2022 | 9.77B | 2.29B | 30.69% |
| Dec 31, 2021 | 7.47B | 5.46B | 270.56% |
| Dec 31, 2020 | 2.02B | -965.08M | -32.37% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Jiangsu Hengrui Pharmaceuticals Co.,Ltd | 30.98B |
| WuXi AppTec | 43.88B |
| Shenzhen Mindray Bio-Medical Electronics | 33.07B |
| Sichuan Biokin Pharmaceutical | 2.23B |
| Shanghai United Imaging Healthcare | 12.20B |
| Aier Eye Hospital Group | 22.17B |
| Zhangzhou Pientzehuang Pharmaceutical., | 9.78B |
| Yunnan Baiyao Group Co.,Ltd | 40.77B |
BeOne Medicines AG News
- 4 weeks ago - BeiGene Non-GAAP EPADS of $2.65, revenue of $1.4B beats by $40M - Seeking Alpha
- 4 weeks ago - BeiGene Q3 2025 Earnings Preview - Seeking Alpha
- 3 months ago - BeOne Cashes In On Amgen's Cancer Drug Royalties In Multibillion-Dollar Pharma Tie-Up - Benzinga
- 4 months ago - A Glimpse of BeiGene's Earnings Potential - Benzinga
- 4 months ago - BeiGene's Earnings: A Preview - Benzinga
- 4 months ago - BeiGene Q2 2025 Earnings Preview - Seeking Alpha
- 5 months ago - Glenmark Pharmaceuticals launches TEVIMBRA in India for advanced lung and esophageal cancer treatment - Business Upturn
- 6 months ago - Glenmark Pharmaceuticals to launch Zanubrutinib (BRUKINSA) in India after DCGI approval - Business Upturn